Grupo Auguri has acquired a controlling interest in Clínica Las Condes S.A.
Grupo Auguri has acquired a controlling interest in Clínica Las Condes S.A.
Grupo Auguri is a Chilean family office linked to the Karlezi Solari family, which have investments in multiple companies from various industries throughout the country and abroad.
Based in Santiago, Clínica Las Condes is one of the largest private hospitals in Chile. The company initiated its operations in 1982 with a focus on high complexity medicine. Its services include inpatient medical, surgical intensive care units, intermediate, adult, pediatric, neonatal, surgical wards, post-recovery operative, clinical laboratories, radiology, CT magnetic resonance imaging, radiation therapy, PET-CT, nuclear medicine, ultrasound, dialysis and other services that include outpatient procedures.
Oaklins’ team in Chile acted as financial advisor to Grupo Auguri in this transaction.


Contáctese con el equipo de la transacción
Transacciones relacionadas
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Aprenda másAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Aprenda másXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Aprenda más